Sign In
Buy CYAD
$0.470
+0 (+0%)
At Close: Aug 17, 2023
Celyad: Early Stage CAR-T Company With A Different Approach
02:55pm, Wednesday, 11'th Mar 2020
Celyad is developing both an autologous and allogeneic CAR-T platform to treat both hematological malignancies and solid tumors. Its lead allogeneic product can
Celyad Appoints Stephen Rubino as Chief Business Officer
06:00am, Monday, 02'nd Mar 2020
MONT-SAINT-GUIBERT, Belgium, March 02, 2020 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
Celyad Announces February and March 2020 Conference Schedule
06:00am, Monday, 17'th Feb 2020
MONT-SAINT-GUIBERT, Belgium, Feb. 17, 2020 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
Analyzing Myokardia (NASDAQ:MYOK) and CELYAD SA/ADR (NASDAQ:CYAD)
07:18am, Thursday, 30'th Jan 2020
Myokardia (NASDAQ:MYOK) and CELYAD SA/ADR (NASDAQ:CYAD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recomm
Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS
06:00am, Monday, 13'th Jan 2020
MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T
Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting
11:30pm, Monday, 09'th Dec 2019
Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary OptimAb manufacturing.
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
01:35pm, Saturday, 07'th Dec 2019
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDA
Celyad Receives Additional €2.5 Million in Non-Dilutive Funding
06:00am, Friday, 06'th Dec 2019
MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
